Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer
During the past decade, immunotherapy has dramatically improved the outcomes of patients with non-small cell lung cancer (NSCLC). The development of specific antibodies against the programmed death (PD1) receptor and its ligand PD-L1 (programmed death ligand-1) has demonstrated substantial efficacy...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.962947/full |
| _version_ | 1811205270498443264 |
|---|---|
| author | Claudio Martin Claudio Martin Diego Enrico Diego Enrico |
| author_facet | Claudio Martin Claudio Martin Diego Enrico Diego Enrico |
| author_sort | Claudio Martin |
| collection | DOAJ |
| description | During the past decade, immunotherapy has dramatically improved the outcomes of patients with non-small cell lung cancer (NSCLC). The development of specific antibodies against the programmed death (PD1) receptor and its ligand PD-L1 (programmed death ligand-1) has demonstrated substantial efficacy in advanced NSCLC either in the first or in the second line. However, the success of immune checkpoint inhibitors (ICIs) as monotherapy did not reach all patients and long-term responders still represent a small subset of cases. Under these circumstances, different strategies have been and are being tested to optimize clinical outcomes. Here, we reviewed the current evidence and the more promising perspectives of ICI combination approaches, such as the addition of chemotherapy, antiangiogenic agents, other co-inhibitory or co-stimulatory checkpoints, and targeted therapies. |
| first_indexed | 2024-04-12T03:29:10Z |
| format | Article |
| id | doaj.art-0fdfbd8040c74e3192577d0a86407d30 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-12T03:29:10Z |
| publishDate | 2022-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-0fdfbd8040c74e3192577d0a86407d302022-12-22T03:49:36ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-12-011210.3389/fonc.2022.962947962947Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancerClaudio Martin0Claudio Martin1Diego Enrico2Diego Enrico3Department of Medical Oncology, Thoracic Oncology Section, Alexander Fleming Cancer Institute, Buenos Aires, ArgentinaDepartment of Clinical Research, Alexander Fleming Cancer Institute, Buenos Aires, ArgentinaDepartment of Medical Oncology, Thoracic Oncology Section, Alexander Fleming Cancer Institute, Buenos Aires, ArgentinaDepartment of Clinical Research, Alexander Fleming Cancer Institute, Buenos Aires, ArgentinaDuring the past decade, immunotherapy has dramatically improved the outcomes of patients with non-small cell lung cancer (NSCLC). The development of specific antibodies against the programmed death (PD1) receptor and its ligand PD-L1 (programmed death ligand-1) has demonstrated substantial efficacy in advanced NSCLC either in the first or in the second line. However, the success of immune checkpoint inhibitors (ICIs) as monotherapy did not reach all patients and long-term responders still represent a small subset of cases. Under these circumstances, different strategies have been and are being tested to optimize clinical outcomes. Here, we reviewed the current evidence and the more promising perspectives of ICI combination approaches, such as the addition of chemotherapy, antiangiogenic agents, other co-inhibitory or co-stimulatory checkpoints, and targeted therapies.https://www.frontiersin.org/articles/10.3389/fonc.2022.962947/fullnon-small-cell lung cancerimmunotherapyimmune checkpoint inhibitorscombinationschemotherapyantiangiogenic |
| spellingShingle | Claudio Martin Claudio Martin Diego Enrico Diego Enrico Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer Frontiers in Oncology non-small-cell lung cancer immunotherapy immune checkpoint inhibitors combinations chemotherapy antiangiogenic |
| title | Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer |
| title_full | Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer |
| title_fullStr | Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer |
| title_full_unstemmed | Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer |
| title_short | Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer |
| title_sort | current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non small cell lung cancer |
| topic | non-small-cell lung cancer immunotherapy immune checkpoint inhibitors combinations chemotherapy antiangiogenic |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.962947/full |
| work_keys_str_mv | AT claudiomartin currentandnoveltherapeuticstrategiesforoptimizingimmunotherapyoutcomesinadvancednonsmallcelllungcancer AT claudiomartin currentandnoveltherapeuticstrategiesforoptimizingimmunotherapyoutcomesinadvancednonsmallcelllungcancer AT diegoenrico currentandnoveltherapeuticstrategiesforoptimizingimmunotherapyoutcomesinadvancednonsmallcelllungcancer AT diegoenrico currentandnoveltherapeuticstrategiesforoptimizingimmunotherapyoutcomesinadvancednonsmallcelllungcancer |